首页 > 最新文献

Kansas Journal of Medicine最新文献

英文 中文
Comprehension Profile of Patient Education Materials in Endocrine Care. 内分泌护理患者教材的理解情况。
Pub Date : 2022-07-21 eCollection Date: 2022-01-01 DOI: 10.17161/kjm.vol15.16529
Som P Singh, Fahad M Qureshi, Kiera G Borthwick, Sagar Singh, Shreya Menon, Brandon Barthel

Introduction: The internet is an ever-evolving resource to improve healthcare literacy among patients. The nature of the internet can make it difficult to condense educational materials in a manner applicable to a worldwide patient audience. Within the realm of endocrinology, there is lack of a comprehensive analysis regarding these pathologies in addition to education materials related to their medical work-up or management. The aim of this study was to assess contemporary online patient education material in endocrinology and management of care.

Methods: Analysis of the readability of 1,500 unique online education materials was performed utilizing seven readability measures: Flesch Reading Ease (FRE), Flesch-Kincaid Grade Level (FKGL), Gunning Fog Index Readability Formula (FOG), Simple Measure of Gobbledygook Index (SMOG), Coleman-Liau Index (CLI), automated readability index (ARI), and Linsear Write Formula (LWF).

Results: The average grade level readability scores from six measures (e.g., FKGL, FOG, SMOG, CLI, ARI, LWF) was more than or equal to 11 which corresponds to a reading level at or above the 11th grade. The average FRE between adrenal, diabetes, and thyroid-related education m aterial ranged between "fairly difficult" to "very difficult".

Conclusions: The readability of contemporary online endocrine education material did not meet current readability recommendations for appropriate comprehension of the general audience.

互联网是一种不断发展的资源,可以提高患者的医疗保健素养。互联网的性质可能使其难以以一种适用于全世界耐心的听众的方式浓缩教育材料。在内分泌学领域,除了与其医疗检查或管理相关的教育材料外,还缺乏对这些病理的全面分析。本研究的目的是评估内分泌学和护理管理方面的当代在线患者教育材料。方法:采用Flesch Reading Ease (FRE)、Flesch- kincaid Grade Level (FKGL)、Gunning Fog Index可读性公式(Fog)、Simple Measure of Gobbledygook Index (SMOG)、Coleman-Liau Index (CLI)、automated可读性指数(ARI)和Linsear Write Formula (LWF) 7种可读性指标对1500种独特的在线教材进行可读性分析。结果:FKGL、FOG、SMOG、CLI、ARI、LWF等6项测试的平均年级阅读水平得分大于等于11分,对应于11年级以上的阅读水平。肾上腺、糖尿病和甲状腺相关教育材料的平均FRE介于“相当难”到“非常难”之间。结论:当代在线内分泌教育材料的可读性不符合当前推荐的一般受众适当理解的可读性。
{"title":"Comprehension Profile of Patient Education Materials in Endocrine Care.","authors":"Som P Singh,&nbsp;Fahad M Qureshi,&nbsp;Kiera G Borthwick,&nbsp;Sagar Singh,&nbsp;Shreya Menon,&nbsp;Brandon Barthel","doi":"10.17161/kjm.vol15.16529","DOIUrl":"https://doi.org/10.17161/kjm.vol15.16529","url":null,"abstract":"<p><strong>Introduction: </strong>The internet is an ever-evolving resource to improve healthcare literacy among patients. The nature of the internet can make it difficult to condense educational materials in a manner applicable to a worldwide patient audience. Within the realm of endocrinology, there is lack of a comprehensive analysis regarding these pathologies in addition to education materials related to their medical work-up or management. The aim of this study was to assess contemporary online patient education material in endocrinology and management of care.</p><p><strong>Methods: </strong>Analysis of the readability of 1,500 unique online education materials was performed utilizing seven readability measures: Flesch Reading Ease (FRE), Flesch-Kincaid Grade Level (FKGL), Gunning Fog Index Readability Formula (FOG), Simple Measure of Gobbledygook Index (SMOG), Coleman-Liau Index (CLI), automated readability index (ARI), and Linsear Write Formula (LWF).</p><p><strong>Results: </strong>The average grade level readability scores from six measures (e.g., FKGL, FOG, SMOG, CLI, ARI, LWF) was more than or equal to 11 which corresponds to a reading level at or above the 11th grade. The average FRE between adrenal, diabetes, and thyroid-related education m aterial ranged between \"fairly difficult\" to \"very difficult\".</p><p><strong>Conclusions: </strong>The readability of contemporary online endocrine education material did not meet current readability recommendations for appropriate comprehension of the general audience.</p>","PeriodicalId":17991,"journal":{"name":"Kansas Journal of Medicine","volume":" ","pages":"247-252"},"PeriodicalIF":0.0,"publicationDate":"2022-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5f/cd/15-247.PMC9311631.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40638066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Scleroderma as an Uncommon Cause of Pericardial Effusion. 硬皮病是心包积液的罕见病因。
Pub Date : 2022-07-21 eCollection Date: 2022-01-01 DOI: 10.17161/kjm.vol15.17026
Brianna L Yee, Neilmegh L Varada, Osman M Rahimi, Chriselyn F Palma, Omar S Al-Taweel, Chowdhury H Ahsan
257 Scleroderma as an Uncommon Cause of Pericardial Effusion Brianna L. Yee, M.D., Neilmegh L. Varada, D.O., Osman M. Rahimi, D.O., Chriselyn F. Palma, D.O., Omar S. Al-Taweel, M.D., Chowdhury H. Ahsan, M.D. University of Nevada-Las Vegas, Kirk Kerkorian School of Medicine, Las Vegas, NV Received March 21, 2022; Accepted for publication May 16, 2022; Published online July 21, 2022 https://doi.org/10.17161/kjm.vol15.17026
{"title":"Scleroderma as an Uncommon Cause of Pericardial Effusion.","authors":"Brianna L Yee,&nbsp;Neilmegh L Varada,&nbsp;Osman M Rahimi,&nbsp;Chriselyn F Palma,&nbsp;Omar S Al-Taweel,&nbsp;Chowdhury H Ahsan","doi":"10.17161/kjm.vol15.17026","DOIUrl":"https://doi.org/10.17161/kjm.vol15.17026","url":null,"abstract":"257 Scleroderma as an Uncommon Cause of Pericardial Effusion Brianna L. Yee, M.D., Neilmegh L. Varada, D.O., Osman M. Rahimi, D.O., Chriselyn F. Palma, D.O., Omar S. Al-Taweel, M.D., Chowdhury H. Ahsan, M.D. University of Nevada-Las Vegas, Kirk Kerkorian School of Medicine, Las Vegas, NV Received March 21, 2022; Accepted for publication May 16, 2022; Published online July 21, 2022 https://doi.org/10.17161/kjm.vol15.17026","PeriodicalId":17991,"journal":{"name":"Kansas Journal of Medicine","volume":" ","pages":"257-258"},"PeriodicalIF":0.0,"publicationDate":"2022-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d2/27/15-257.PMC9311772.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40638072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Bilateral Upper Lobe Collapse Secondary to Vaping. 双侧上肺叶塌陷继发于吸电子烟。
Pub Date : 2022-07-21 eCollection Date: 2022-01-01 DOI: 10.17161/kjm.vol15.17003
Nicholas Tuck, Karen Gichohi, Thomas Moore
253 Bilateral Upper Lobe Collapse Secondary to Vaping Nicholas Tuck, M.D.1, Karen Gichohi, M.D.1, Thomas Moore, M.D., FACP, FIDSA1,2 1University of Kansas School of Medicine-Wichita, Wichita, KS Department of Internal Medicine 2Infectious Disease Consultants, Wichita, KS Received March 12, 2022; Accepted for publication April 25, 2022; Published online July 21, 2022 https://doi.org/10.17161/kjm.vol15.17003
{"title":"Bilateral Upper Lobe Collapse Secondary to Vaping.","authors":"Nicholas Tuck,&nbsp;Karen Gichohi,&nbsp;Thomas Moore","doi":"10.17161/kjm.vol15.17003","DOIUrl":"https://doi.org/10.17161/kjm.vol15.17003","url":null,"abstract":"253 Bilateral Upper Lobe Collapse Secondary to Vaping Nicholas Tuck, M.D.1, Karen Gichohi, M.D.1, Thomas Moore, M.D., FACP, FIDSA1,2 1University of Kansas School of Medicine-Wichita, Wichita, KS Department of Internal Medicine 2Infectious Disease Consultants, Wichita, KS Received March 12, 2022; Accepted for publication April 25, 2022; Published online July 21, 2022 https://doi.org/10.17161/kjm.vol15.17003","PeriodicalId":17991,"journal":{"name":"Kansas Journal of Medicine","volume":" ","pages":"253-254"},"PeriodicalIF":0.0,"publicationDate":"2022-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/25/d7/15-253.PMC9311635.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40639948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient Controlled Analgesia and an Alternative Protocol: A Comparison of Outcomes After Thoracic and Lumbar Surgery. 患者自控镇痛和替代方案:胸椎和腰椎手术后疗效的比较。
Pub Date : 2022-07-21 eCollection Date: 2022-01-01 DOI: 10.17161/kjm.vol15.15972
Will Donelson, Joey Dean, Elizabeth Ablah, Clara Whitaker, Gina M Berg, Kyle McCormick, Hayrettin Okut, Camden Whitaker

Introduction: Patient controlled analgesia (PCA) is a common form of pain management after spine surgeries, in which patients get custom control of their opioid dose. PCA has been demonstrated as a safe form of analgesia; however, use of PCA comes with risks that can be mitigated by opting for alternative pain management. This study aimed to compare the outcomes of patients using PCA to those with an alternative analgesia protocol that does not involve PCA.

Methods: A retrospective chart review from January 2017 to July 2018 was conducted. Patients included in this study were those 18 or older who were admitted to a large midwestern tertiary medical center in Wichita, Kansas, and underwent thoracic or lumbar spinal surgery from a single spine surgeon. Data from patient demographics, comorbidities, and type of procedure were collected and compared to control for possible confounding variables. Patients were divided into two groups: patients receiving a PCA pain protocol post-operatively and those receiving a non-PCA protocol. Statistical analyses were performed and all tests with p < 0.05 were considered significant.

Results: This study found patients in the PCA protocol had similar outcomes to those in the alternative analgesia protocol. This was true for both primary and secondary outcomes. The primary outcome was patient length of stay after the operation. Secondary outcomes included readmission rates, frequency of naloxone rescue, transfers to higher levels of care, and total opioid consumption.

Conclusions: This study supported that a non-PCA protocol for post-operative pain management yields similar outcomes to a PCA protocol in the setting of thoracic and lumbar surgery.

患者自控镇痛(PCA)是脊柱手术后疼痛管理的一种常见形式,患者可以自定义控制其阿片类药物剂量。PCA已被证明是一种安全的镇痛形式;然而,使用PCA带来的风险可以通过选择其他疼痛管理来减轻。本研究旨在比较使用PCA的患者与不使用PCA的替代镇痛方案的患者的结果。方法:对2017年1月至2018年7月的病例进行回顾性分析。本研究纳入的患者为18岁或以上,他们在堪萨斯州威奇托的一家大型中西部三级医疗中心就诊,并接受了同一位脊柱外科医生的胸椎或腰椎手术。收集患者人口统计学、合并症和手术类型的数据,并与可能的混杂变量进行比较。患者被分为两组:术后接受PCA疼痛方案的患者和接受非PCA方案的患者。进行统计学分析,p < 0.05为显著性。结果:本研究发现,采用PCA方案的患者与采用替代镇痛方案的患者预后相似。主要和次要结果都是如此。主要观察指标是术后患者的住院时间。次要结局包括再入院率、纳洛酮抢救频率、转至更高级别护理和阿片类药物总消费量。结论:本研究支持在胸椎和腰椎手术中,非PCA方案用于术后疼痛管理的结果与PCA方案相似。
{"title":"Patient Controlled Analgesia and an Alternative Protocol: A Comparison of Outcomes After Thoracic and Lumbar Surgery.","authors":"Will Donelson,&nbsp;Joey Dean,&nbsp;Elizabeth Ablah,&nbsp;Clara Whitaker,&nbsp;Gina M Berg,&nbsp;Kyle McCormick,&nbsp;Hayrettin Okut,&nbsp;Camden Whitaker","doi":"10.17161/kjm.vol15.15972","DOIUrl":"https://doi.org/10.17161/kjm.vol15.15972","url":null,"abstract":"<p><strong>Introduction: </strong>Patient controlled analgesia (PCA) is a common form of pain management after spine surgeries, in which patients get custom control of their opioid dose. PCA has been demonstrated as a safe form of analgesia; however, use of PCA comes with risks that can be mitigated by opting for alternative pain management. This study aimed to compare the outcomes of patients using PCA to those with an alternative analgesia protocol that does not involve PCA.</p><p><strong>Methods: </strong>A retrospective chart review from January 2017 to July 2018 was conducted. Patients included in this study were those 18 or older who were admitted to a large midwestern tertiary medical center in Wichita, Kansas, and underwent thoracic or lumbar spinal surgery from a single spine surgeon. Data from patient demographics, comorbidities, and type of procedure were collected and compared to control for possible confounding variables. Patients were divided into two groups: patients receiving a PCA pain protocol post-operatively and those receiving a non-PCA protocol. Statistical analyses were performed and all tests with p < 0.05 were considered significant.</p><p><strong>Results: </strong>This study found patients in the PCA protocol had similar outcomes to those in the alternative analgesia protocol. This was true for both primary and secondary outcomes. The primary outcome was patient length of stay after the operation. Secondary outcomes included readmission rates, frequency of naloxone rescue, transfers to higher levels of care, and total opioid consumption.</p><p><strong>Conclusions: </strong>This study supported that a non-PCA protocol for post-operative pain management yields similar outcomes to a PCA protocol in the setting of thoracic and lumbar surgery.</p>","PeriodicalId":17991,"journal":{"name":"Kansas Journal of Medicine","volume":" ","pages":"237-240"},"PeriodicalIF":0.0,"publicationDate":"2022-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/08/15-237.PMC9311771.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40638067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Association of Metabolic-Associated Fatty Liver Disease with Clinical Outcomes of COVID-19: A Systematic Review and Meta-Analysis. 代谢性脂肪性肝病与COVID-19临床结局的关联:系统综述和荟萃分析
Pub Date : 2022-07-21 eCollection Date: 2022-01-01 DOI: 10.17161/kjm.vol15.16522
Umar Hayat, Muhammad Zubair Ashfaq, Luke Johnson, Ryan Ford, Chelsea Wuthnow, Kevin Kadado, Katia El Jurdi, Hayrettin Okut, William Ransom Kilgore, Maha Assi, Ali A Siddiqui

Introduction: Metabolic-associated fatty liver disease (MAFLD) is a hepatic manifestation of metabolic syndrome (MS). MAFLD patients have a higher prevalence of COVID-19. MAFLD also is associated with worse clinical outcomes of COVID-19, such as disease severity, intensive care unit (ICU) admission rate, and higher mortality rates. However, this evidence has not been well characterized in the literature. This meta-analysis aimed to determine the clinical outcomes of COVID-19 among MAFLD patients compared to the non-MAFLD group.

Methods: A comprehensive search was conducted in the Cumulative Index of Nursing and Allied Health (CINAHL), PubMed/Medline, and Embase for studies reporting MAFLD prevalence among COVID-19 patients and comparing clinical outcomes such as severity, ICU admission, and mortality among patients with and without MAFLD. The pooled prevalence of MAFLD among COVID-19 patients and the pooled odds ratios (OR) with 95% confidence intervals (CI) for clinical outcomes of COVID-19 were calculated.

Results: Sixteen observational studies met inclusion criteria involving a total of 11,484 overall study participants, including 1,746 MAFLD patients. The prevalence of COVID-19 among MAFLD patients was 0.29 (95% CI: 0.19-0.40). MAFLD was associated with the COVID-19 disease severity OR 3.07 (95% CI: 2.30-4.09). Similarly, MAFLD was associated with an increased risk of ICU admission compared to the non-MAFLD group OR 1.46 (95% CI: 1.12-1.91). Lastly, the association between MAFLD and COVID-19 mortality was not statistically significant OR 1.45 (95% CI: 0.74-2.84).

Conclusions: In this study, a high percentage of COVID-19 patients had MAFLD. Moreover, MAFLD patients had an increased risk of COVID-19 disease severity and ICU admission rate.

代谢相关脂肪性肝病(MAFLD)是代谢综合征(MS)的一种肝脏表现。MAFLD患者的COVID-19患病率较高。MAFLD还与COVID-19更差的临床结果相关,如疾病严重程度、重症监护病房(ICU)入院率和更高的死亡率。然而,这一证据并没有在文献中得到很好的描述。本荟萃分析旨在确定与非MAFLD组相比,MAFLD患者中COVID-19的临床结果。方法:在护理与联合健康累积指数(CINAHL)、PubMed/Medline和Embase中进行综合检索,以报告COVID-19患者中MAFLD患病率的研究,并比较有和无MAFLD患者的临床结果,如严重程度、ICU住院率和死亡率。计算COVID-19患者中MAFLD的合并患病率以及COVID-19临床结局的合并优势比(OR)和95%可信区间(CI)。结果:16项观察性研究符合纳入标准,共纳入11,484名研究参与者,包括1,746名MAFLD患者。MAFLD患者中COVID-19的患病率为0.29 (95% CI: 0.19-0.40)。MAFLD与COVID-19疾病严重程度相关OR为3.07 (95% CI: 2.30-4.09)。同样,与非MAFLD组相比,MAFLD与ICU入院风险增加相关,OR为1.46 (95% CI: 1.12-1.91)。最后,MAFLD与COVID-19死亡率之间的相关性无统计学意义(OR 1.45) (95% CI: 0.74-2.84)。结论:在本研究中,很高比例的COVID-19患者患有MAFLD。此外,MAFLD患者发生COVID-19疾病严重程度和ICU住院率的风险增加。
{"title":"The Association of Metabolic-Associated Fatty Liver Disease with Clinical Outcomes of COVID-19: A Systematic Review and Meta-Analysis.","authors":"Umar Hayat, Muhammad Zubair Ashfaq, Luke Johnson, Ryan Ford, Chelsea Wuthnow, Kevin Kadado, Katia El Jurdi, Hayrettin Okut, William Ransom Kilgore, Maha Assi, Ali A Siddiqui","doi":"10.17161/kjm.vol15.16522","DOIUrl":"10.17161/kjm.vol15.16522","url":null,"abstract":"<p><strong>Introduction: </strong>Metabolic-associated fatty liver disease (MAFLD) is a hepatic manifestation of metabolic syndrome (MS). MAFLD patients have a higher prevalence of COVID-19. MAFLD also is associated with worse clinical outcomes of COVID-19, such as disease severity, intensive care unit (ICU) admission rate, and higher mortality rates. However, this evidence has not been well characterized in the literature. This meta-analysis aimed to determine the clinical outcomes of COVID-19 among MAFLD patients compared to the non-MAFLD group.</p><p><strong>Methods: </strong>A comprehensive search was conducted in the Cumulative Index of Nursing and Allied Health (CINAHL), PubMed/Medline, and Embase for studies reporting MAFLD prevalence among COVID-19 patients and comparing clinical outcomes such as severity, ICU admission, and mortality among patients with and without MAFLD. The pooled prevalence of MAFLD among COVID-19 patients and the pooled odds ratios (OR) with 95% confidence intervals (CI) for clinical outcomes of COVID-19 were calculated.</p><p><strong>Results: </strong>Sixteen observational studies met inclusion criteria involving a total of 11,484 overall study participants, including 1,746 MAFLD patients. The prevalence of COVID-19 among MAFLD patients was 0.29 (95% CI: 0.19-0.40). MAFLD was associated with the COVID-19 disease severity OR 3.07 (95% CI: 2.30-4.09). Similarly, MAFLD was associated with an increased risk of ICU admission compared to the non-MAFLD group OR 1.46 (95% CI: 1.12-1.91). Lastly, the association between MAFLD and COVID-19 mortality was not statistically significant OR 1.45 (95% CI: 0.74-2.84).</p><p><strong>Conclusions: </strong>In this study, a high percentage of COVID-19 patients had MAFLD. Moreover, MAFLD patients had an increased risk of COVID-19 disease severity and ICU admission rate.</p>","PeriodicalId":17991,"journal":{"name":"Kansas Journal of Medicine","volume":" ","pages":"241-246"},"PeriodicalIF":0.0,"publicationDate":"2022-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c8/5f/15-241.PMC9311786.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40638073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Takotsubo Cardiomyopathy in a Vaccinated Patient with Severe COVID-19. 重症COVID-19疫苗接种患者Takotsubo心肌病的研究
Pub Date : 2022-07-21 eCollection Date: 2022-01-01 DOI: 10.17161/kjm.vol15.16456
Osman Rahimi, Neilmegh Varada, Chriselyn Palma, Omar Al Taweel, Kachon Lei, Dalia Hawwass, Chowdhury Ahsan
Takotsubo Cardiomyopathy in a Vaccinated Patient with Severe COVID-19 Osman Rahimi, D.O., Neilmegh Varada, D.O., Chriselyn Palma, D.O., Omar Al Taweel, M.D., Kachon Lei, M.D., Dalia Hawwass, M.D., Chowdhury Ahsan, M.D., Ph.D. University of Nevada-Las Vegas, Kirk Kerkorian School of Medicine, Las Vegas, NV Received Feb. 7, 2022; Accepted for publication April 26, 2022; Published online July 21, 2022 https://doi.org/10.17161/kjm.vol15.16456
{"title":"Takotsubo Cardiomyopathy in a Vaccinated Patient with Severe COVID-19.","authors":"Osman Rahimi,&nbsp;Neilmegh Varada,&nbsp;Chriselyn Palma,&nbsp;Omar Al Taweel,&nbsp;Kachon Lei,&nbsp;Dalia Hawwass,&nbsp;Chowdhury Ahsan","doi":"10.17161/kjm.vol15.16456","DOIUrl":"https://doi.org/10.17161/kjm.vol15.16456","url":null,"abstract":"Takotsubo Cardiomyopathy in a Vaccinated Patient with Severe COVID-19 Osman Rahimi, D.O., Neilmegh Varada, D.O., Chriselyn Palma, D.O., Omar Al Taweel, M.D., Kachon Lei, M.D., Dalia Hawwass, M.D., Chowdhury Ahsan, M.D., Ph.D. University of Nevada-Las Vegas, Kirk Kerkorian School of Medicine, Las Vegas, NV Received Feb. 7, 2022; Accepted for publication April 26, 2022; Published online July 21, 2022 https://doi.org/10.17161/kjm.vol15.16456","PeriodicalId":17991,"journal":{"name":"Kansas Journal of Medicine","volume":" ","pages":"255-256"},"PeriodicalIF":0.0,"publicationDate":"2022-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/88/c4/15-255.PMC9311875.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40638069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Mobile Health Clinics as a Healthcare Delivery Model to Address Community Disparities. 流动医疗诊所作为解决社区差异的医疗服务模式。
Pub Date : 2022-07-21 eCollection Date: 2022-01-01 DOI: 10.17161/kjm.vol15.16543
Som P Singh, Farhan Baig, Shipra Singh
Mobile Health Clinics as a Healthcare Delivery Model to Address Community Disparities Som P. Singh1, Farhan Baig1, Shipra Singh, M.D.1,2 1University of Missouri-Kansas City, School of Medicine, Kansas City, MO 2Central Michigan University, College of Medicine, Saginaw, MI Received Feb. 20, 2022; Accepted for publication April 21, 2022; Published online July 21, 2022 https://doi.org/10.17161/kjm.vol15.16543
{"title":"Mobile Health Clinics as a Healthcare Delivery Model to Address Community Disparities.","authors":"Som P Singh,&nbsp;Farhan Baig,&nbsp;Shipra Singh","doi":"10.17161/kjm.vol15.16543","DOIUrl":"https://doi.org/10.17161/kjm.vol15.16543","url":null,"abstract":"Mobile Health Clinics as a Healthcare Delivery Model to Address Community Disparities Som P. Singh1, Farhan Baig1, Shipra Singh, M.D.1,2 1University of Missouri-Kansas City, School of Medicine, Kansas City, MO 2Central Michigan University, College of Medicine, Saginaw, MI Received Feb. 20, 2022; Accepted for publication April 21, 2022; Published online July 21, 2022 https://doi.org/10.17161/kjm.vol15.16543","PeriodicalId":17991,"journal":{"name":"Kansas Journal of Medicine","volume":" ","pages":"259-261"},"PeriodicalIF":0.0,"publicationDate":"2022-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/64/33/15-259.PMC9311629.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40638071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Hypertension and Cardiovascular Diseases among Electronic and Combustible Cigarette Users. 电子烟和可燃香烟使用者的高血压和心血管疾病。
Pub Date : 2022-07-21 eCollection Date: 2022-01-01 DOI: 10.17161/kjm.vol15.16752
Grace E Falk, Hayrettin Okut, Mohinder R Vindhyal, Elizabeth Ablah

Introduction: Combustible cigarette use is associated with an increased risk of several cardiovascular diseases; however, less is known about associations between these cardiovascular conditions and electronic cigarette use.

Methods: This study investigated relationships between electronic and/or combustible cigarette use and diagnoses of cardiovascular diseases using the National Health Interview Survey from 2014, 2016, 2017, and 2018.

Results: Compared to non-users, dual users of electronic and combustible cigarettes had increased likelihood of having prior diagnoses of hypertension (OR 1.660, 95% CI = 1.519-1.814), stroke (OR 2.396, 95% CI = 2.011-2.855), diabetes mellitus (OR 1.219, 95% CI = 1.108-1.341), coronary artery disease (OR 2.211, 95% CI = 1.837-2.660), and myocardial infarction (OR 3.839, 95% CI = 3.232-4.560). Exclusive use of electronic cigarettes was associated with an increased likelihood of having hypertension compared to non-users (OR 1.244, 95% CI = 1.048-1.477).

Conclusions: There were no differences in diagnoses of stroke, diabetes mellitus, coronary artery disease, or myocardial infarction among exclusive electronic cigarette users compared to non-users; however, these associations could change as young electronic cigarette users with hypertension age, indicating the need for continued research.

导言:可燃香烟的使用与几种心血管疾病的风险增加有关;然而,人们对这些心血管疾病和电子烟使用之间的关系知之甚少。方法:本研究通过2014年、2016年、2017年和2018年的全国健康访谈调查,调查电子和/或可燃卷烟使用与心血管疾病诊断的关系。结果:与非吸烟者相比,电子烟和可燃香烟双重使用者有更高的可能性有高血压(OR 1.660, 95% CI = 1.519-1.814)、中风(OR 2.396, 95% CI = 2.011-2.855)、糖尿病(OR 1.219, 95% CI = 1.108-1.341)、冠状动脉疾病(OR 2.211, 95% CI = 1.837-2.660)和心肌梗死(OR 3.839, 95% CI = 3.232-4.560)的先前诊断。与不吸电子烟的人相比,只吸电子烟的人患高血压的可能性增加(OR 1.244, 95% CI = 1.048-1.477)。结论:纯电子烟使用者与非电子烟使用者在卒中、糖尿病、冠状动脉疾病或心肌梗死的诊断方面没有差异;然而,随着年轻的高血压电子烟使用者年龄的增长,这些关联可能会发生变化,这表明需要继续研究。
{"title":"Hypertension and Cardiovascular Diseases among Electronic and Combustible Cigarette Users.","authors":"Grace E Falk,&nbsp;Hayrettin Okut,&nbsp;Mohinder R Vindhyal,&nbsp;Elizabeth Ablah","doi":"10.17161/kjm.vol15.16752","DOIUrl":"https://doi.org/10.17161/kjm.vol15.16752","url":null,"abstract":"<p><strong>Introduction: </strong>Combustible cigarette use is associated with an increased risk of several cardiovascular diseases; however, less is known about associations between these cardiovascular conditions and electronic cigarette use.</p><p><strong>Methods: </strong>This study investigated relationships between electronic and/or combustible cigarette use and diagnoses of cardiovascular diseases using the National Health Interview Survey from 2014, 2016, 2017, and 2018.</p><p><strong>Results: </strong>Compared to non-users, dual users of electronic and combustible cigarettes had increased likelihood of having prior diagnoses of hypertension (OR 1.660, 95% CI = 1.519-1.814), stroke (OR 2.396, 95% CI = 2.011-2.855), diabetes mellitus (OR 1.219, 95% CI = 1.108-1.341), coronary artery disease (OR 2.211, 95% CI = 1.837-2.660), and myocardial infarction (OR 3.839, 95% CI = 3.232-4.560). Exclusive use of electronic cigarettes was associated with an increased likelihood of having hypertension compared to non-users (OR 1.244, 95% CI = 1.048-1.477).</p><p><strong>Conclusions: </strong>There were no differences in diagnoses of stroke, diabetes mellitus, coronary artery disease, or myocardial infarction among exclusive electronic cigarette users compared to non-users; however, these associations could change as young electronic cigarette users with hypertension age, indicating the need for continued research.</p>","PeriodicalId":17991,"journal":{"name":"Kansas Journal of Medicine","volume":" ","pages":"226-230"},"PeriodicalIF":0.0,"publicationDate":"2022-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ec/9a/15-226.PMC9311785.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40638068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Clinical Outcome of Different Postoperative Prophylactic Strategies on Symptomatic Venous Thromboembolism after Total Knee Arthroplasty. 全膝关节置换术后不同预防策略对症状性静脉血栓栓塞的临床效果。
Pub Date : 2022-07-21 eCollection Date: 2022-01-01 DOI: 10.17161/kjm.vol15.16367
Seth M Wardyn, Alexander C M Chong, Bruce E Piatt

Introduction: The objective of this study was to evaluate the use of different post-operative prophylactic strategies on the rates of symptomatic venous thromboembolic events (VTE) incidence after primary total knee arthroplasty (TKA).

Methods: A retrospective study of patients who underwent primary TKA procedure was performed from January 2015 through July 2020. Outcomes examined prophylaxis medication used during inpatient and outpatient care, amount of medication, length of medication, complications occurring within 90 days post-operatively, including symptomatic VTE (deep venous thrombosis (DVT), and pulmonary embolism (PE)), gastrointestinal (GI) bleeding requiring medical attention, change in management protocols after post-operative complications, and mortality.

Results: In total, 5,663 cases were included (mean age 66 ± 10 years, mean BMI 34.1 ± 7.1kg/m2). The overall post-operative complication rate was 0.9% (DVT: 0.5%, PE: 0.3%, VTE: 0.04%, and GI bleeding: 0.09%). Enoxaparin use as inpatient anticoagulation medication was reduced significantly (67% vs. 13%, p < 0.001), and apixaban was increased significantly (6% vs. 49%, p < 0.001). Average hospital stays were reduced significantly among the years (3 ± 2 days vs. 2 ± 1 days, p < 0.001), and complication rates were not significantly different between the five years (~1%, p < 0.001). Most post-operative complications occurred on either aspirin 325 mg (36%) or apixaban (26%). However, the relative risk ratio results indicating that utilization of warfarin, rivaroxaban, and aspirin 81 mg as outpatient anticoagulation medication were more likely to increase the risk of symptomatic VTE incidence compared to other anticoagulants. The average time of complication detected was 21 ± 21 days (range: 1 - 87 days). More than 54% of complication events occurred after the patient had completed their medication (enoxaparin, rivaroxaban, and apixaban).

Conclusions: The observed incidence of symptomatic VTE in this study was similar to previous studies regardless of the type of post-operative inpatient or outpatient prophylaxis prescribed. The ultimate choice of prophylaxis should remain with the treating physician and their knowledge of a particular patient's medical history.

简介:本研究的目的是评估不同的术后预防策略对原发性全膝关节置换术(TKA)后症状性静脉血栓栓塞事件(VTE)发生率的影响。方法:对2015年1月至2020年7月接受原发性TKA手术的患者进行回顾性研究。结果检查了住院和门诊护理期间使用的预防性药物,药物用量,药物使用时间,术后90天内发生的并发症,包括症状性静脉血栓形成(深静脉血栓形成(DVT)和肺栓塞(PE)),需要医疗护理的胃肠道(GI)出血,术后并发症后管理方案的改变以及死亡率。结果:共纳入5663例,平均年龄66±10岁,平均BMI 34.1±7.1kg/m2。术后总并发症发生率为0.9% (DVT: 0.5%, PE: 0.3%, VTE: 0.04%, GI出血:0.09%)。依诺肝素作为住院抗凝药物的使用显著减少(67%对13%,p < 0.001),阿哌沙班的使用显著增加(6%对49%,p < 0.001)。平均住院时间在年内显著减少(3±2天vs. 2±1天,p < 0.001),并发症发生率在五年内无显著差异(~1%,p < 0.001)。大多数术后并发症发生在阿司匹林325 mg(36%)或阿哌沙班(26%)。然而,相对风险比结果表明,与其他抗凝药物相比,华法林、利伐沙班和阿司匹林81 mg作为门诊抗凝药物更有可能增加症状性静脉血栓栓塞发生率。发现并发症的平均时间为21±21天(范围:1 ~ 87天)。超过54%的并发症发生在患者完成用药(依诺肝素、利伐沙班和阿哌沙班)后。结论:本研究中观察到的症状性静脉血栓栓塞的发生率与以往的研究相似,与术后住院或门诊预防处方的类型无关。预防的最终选择应保留在治疗医生和他们对特定患者的病史的了解。
{"title":"Clinical Outcome of Different Postoperative Prophylactic Strategies on Symptomatic Venous Thromboembolism after Total Knee Arthroplasty.","authors":"Seth M Wardyn,&nbsp;Alexander C M Chong,&nbsp;Bruce E Piatt","doi":"10.17161/kjm.vol15.16367","DOIUrl":"https://doi.org/10.17161/kjm.vol15.16367","url":null,"abstract":"<p><strong>Introduction: </strong>The objective of this study was to evaluate the use of different post-operative prophylactic strategies on the rates of symptomatic venous thromboembolic events (VTE) incidence after primary total knee arthroplasty (TKA).</p><p><strong>Methods: </strong>A retrospective study of patients who underwent primary TKA procedure was performed from January 2015 through July 2020. Outcomes examined prophylaxis medication used during inpatient and outpatient care, amount of medication, length of medication, complications occurring within 90 days post-operatively, including symptomatic VTE (deep venous thrombosis (DVT), and pulmonary embolism (PE)), gastrointestinal (GI) bleeding requiring medical attention, change in management protocols after post-operative complications, and mortality.</p><p><strong>Results: </strong>In total, 5,663 cases were included (mean age 66 ± 10 years, mean BMI 34.1 ± 7.1kg/m<sup>2</sup>). The overall post-operative complication rate was 0.9% (DVT: 0.5%, PE: 0.3%, VTE: 0.04%, and GI bleeding: 0.09%). Enoxaparin use as inpatient anticoagulation medication was reduced significantly (67% vs. 13%, p < 0.001), and apixaban was increased significantly (6% vs. 49%, p < 0.001). Average hospital stays were reduced significantly among the years (3 ± 2 days vs. 2 ± 1 days, p < 0.001), and complication rates were not significantly different between the five years (~1%, p < 0.001). Most post-operative complications occurred on either aspirin 325 mg (36%) or apixaban (26%). However, the relative risk ratio results indicating that utilization of warfarin, rivaroxaban, and aspirin 81 mg as outpatient anticoagulation medication were more likely to increase the risk of symptomatic VTE incidence compared to other anticoagulants. The average time of complication detected was 21 ± 21 days (range: 1 - 87 days). More than 54% of complication events occurred after the patient had completed their medication (enoxaparin, rivaroxaban, and apixaban).</p><p><strong>Conclusions: </strong>The observed incidence of symptomatic VTE in this study was similar to previous studies regardless of the type of post-operative inpatient or outpatient prophylaxis prescribed. The ultimate choice of prophylaxis should remain with the treating physician and their knowledge of a particular patient's medical history.</p>","PeriodicalId":17991,"journal":{"name":"Kansas Journal of Medicine","volume":" ","pages":"231-236"},"PeriodicalIF":0.0,"publicationDate":"2022-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1c/e9/15-231.PMC9311630.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40638070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thiazide-Induced Pancreatitis. Thiazide-Induced胰腺炎。
Pub Date : 2022-06-20 eCollection Date: 2022-01-01 DOI: 10.17161/kjm.vol15.16534
Nourhan Chaaban, Shilpa Kshatriya
INTRODUCTION Acute pancreatitis (AP) is an acute inflammatory disease of the pancreas and is associated with a wide spectrum of clinical manifestations, ranging from mild disease to more severe forms, even requiring intensive care unit hospitalization.1 The reported annual incidence of acute pancreatitis in the United States ranges from 4.9 to 35 per 100,000 population.2 Pancreatitis due to medications is rare (< 5%).3 Published reports have identified about 50 drugs that definitely or possibly may be held responsible for inducing acute pancreatitis.4 Also, the global prevalence of hypertension is high, and among nonpregnant adults in the United States, treatment of hypertension is the most common reason for office visits and the use of chronic prescription medications.5 Drug-induced pancreatitis remains a challenge for physicians. It needs further consideration when a patient has a clinical presentation suggestive of acute pancreatitis without a significant cause. This report involved a case of hydrochlorothiazide-induced pancreatitis in a patient who recently had started this medication for blood pressure control. We aimed to determine the association of thiazide drugs with the incidence of pancreatitis and add to the literature this rare case.
{"title":"Thiazide-Induced Pancreatitis.","authors":"Nourhan Chaaban,&nbsp;Shilpa Kshatriya","doi":"10.17161/kjm.vol15.16534","DOIUrl":"https://doi.org/10.17161/kjm.vol15.16534","url":null,"abstract":"INTRODUCTION Acute pancreatitis (AP) is an acute inflammatory disease of the pancreas and is associated with a wide spectrum of clinical manifestations, ranging from mild disease to more severe forms, even requiring intensive care unit hospitalization.1 The reported annual incidence of acute pancreatitis in the United States ranges from 4.9 to 35 per 100,000 population.2 Pancreatitis due to medications is rare (< 5%).3 Published reports have identified about 50 drugs that definitely or possibly may be held responsible for inducing acute pancreatitis.4 Also, the global prevalence of hypertension is high, and among nonpregnant adults in the United States, treatment of hypertension is the most common reason for office visits and the use of chronic prescription medications.5 Drug-induced pancreatitis remains a challenge for physicians. It needs further consideration when a patient has a clinical presentation suggestive of acute pancreatitis without a significant cause. This report involved a case of hydrochlorothiazide-induced pancreatitis in a patient who recently had started this medication for blood pressure control. We aimed to determine the association of thiazide drugs with the incidence of pancreatitis and add to the literature this rare case.","PeriodicalId":17991,"journal":{"name":"Kansas Journal of Medicine","volume":" ","pages":"220-221"},"PeriodicalIF":0.0,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/83/ee/15-220.PMC9225032.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40406343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Kansas Journal of Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1